Bedford Laboratories™ to Begin Shipping Fluconazole Injection

BEDFORD, OH – January 15, 2010 – Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce FDA approval for the addition of 100 mg/50 mL Fluconazole Injection to its existing Fluconazole Injection line. This product is AP rated and is equivalent to Diflucan® by Pfizer. Fluconazole Injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated for the prophylaxis of candidiasis.

 

“Pharmacists asked, we answered. In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to be the first to offer this unique dosage. Fluconazole Injection 100 mg/50 mL is right-sized for smaller doses, speeding productivity and saving time. This continues to demonstrate our commitment to providing a broad-based portfolio of products,” said David Gaugh, Vice President of Bedford Laboratories.
Bedford Laboratories will supply Fluconazole Injection sterile iso-osmotic solution containing 2 mg/mL of fluconazole in glass vials in the following presentations: Vials containing either 100 mg, 200 mg or 400 mg equivalent of fluconazole. In addition, Bedford Laboratories will supply Fluconazole Injection as a sterile iso-osmotic solution containing 2 mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations: 200 mg/100 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400 mg/200 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.

 

Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.

 

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
 

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
 

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
 

In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
 

For more information, please visit http://us.boehringer-ingelheim.com.

 

 

Bedford Laboratories to Begin Shipping Ceftriaxone for

Injection USP

BEDFORD, OH – July 16, 2009 – Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. This product is AP rated and is equivalent to Rocephin® by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to treat several types of infections caused by susceptible bacteria.
 

“In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product which represents Bedford’s entry into the cephalosporin market. This continues to demonstrate our commitment to providing a broad based portfolio of products,” said David Gaugh, Vice President and General Manager of Bedford Laboratories.

 

Bedford Laboratories will supply Ceftriaxone for Injection USP as a sterile crystalline powder in glass vials in the following presentations:  Single-dose vials containing either 250mg, 500mg, 1g, or 2g equivalent of ceftriaxone packaged in cartons containing 10 vials and a pharmacy bulk vial containing the equivalent of 10g ceftriaxone packaged in cartons containing 1 vial.

 

Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s Web site, www.bedfordlabs.com.
 

Rocephin® is a registered trademark of Hoffmann-La Roche, Inc.

 

Bedford Laboratories™ to Begin Shipping Fluconazole Injection in PVC Flexible Containers

BEDFORD, OH – April 13, 2009 – Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., announced the addition of Fluconazole injection 2 mg / mL in PVC flexible containers to its existing Fluconazole injection line.  This product is AP rated and is equivalent to Diflucan® by Pfizer.  Fluconazole injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is also indicated for the prophylaxis of candidiasis.

“In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product in PVC flexible containers.  This product represents Bedford’s entry into the I.V. bag market and demonstrates our ongoing commitment to providing a broad based portfolio of products” said David Gaugh, Vice President of Bedford Laboratories.

In addition to the glass vial presentations, Bedford Laboratories will supply Fluconazole injection as a sterile iso-osmotic solution containing 2mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations:  200mg / 100mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400mg / 200mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.

Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.

 
 
Bedford Laboratories™ to Begin Shipping Irinotecan HCl Injection

BEDFORD, OH – January 29, 2009 – Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., announced the launch of Irinotecan HCl Injection.  This product is AP rated and is equivalent to Camptosar®.  Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.  This product is available for immediate shipment nationwide. 

Bedford Laboratories will supply Irinotecan HCl Injection as a sterile aqueous solution available in two different dosages including 40mg / 2mL single dose amber vials individually boxed and 100mg / 5mL single dose amber vials individually boxed.

Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169 or from their web site, www.bedfordlabs.com.

Camptosar® is a registered trademark of Pfizer.
Ben Venue Laboratories, Inc. Named Recipient of the Governor’s Award for Outstanding Achievement in Environmental Stewardship

 

BEDFORD, OH – December 8, 2008 – Ben Venue Laboratories, Inc. is pleased to be the recipient of the 2008 Governor’s Award for Outstanding Achievement in Environmental Stewardship presented by Governor Ted Strickland and the State of Ohio Environmental Protection Agency on December 3, 2008.  The award recognizes Ben Venue for its environmental, health and safety management system that strives to promote a safe and healthy manufacturing environment, including brownfield reuse and re-development, LEED (Leadership in Energy and Environmental Design) construction design and application for Silver Certification for its recently completed 90,000 square foot Lab and Office facility, recycling and reuse, energy saving, and water conservation.

 

Coordinated by the Ohio EPA, the award seeks to acknowledge Ohio businesses and organizations demonstrating a commitment to go above and beyond compliance, maintain aggressive environmental performance goals, and provide a process for communicating with others about program activities and progress toward established goals. Submitted nominations were rated and the Ohio EPA completed site audits with the finalists to select the eight chosen honorees.  "I'm honored to recognize these forward-thinking award winners, which have all demonstrated cutting-edge achievements and a commitment to environmental stewardship in Ohio," said Ohio EPA Director Chris Korleski in a press release issued by the Governor’s office.  Governor Ted Strickland added "These companies are leaders in protecting Ohio's natural resources while implementing innovative approaches that reduced the cost of doing business, improved company efficiency, and enhanced the quality of life and the environment in their communities. I commend their efforts," More information about the award is available at: http://www.epa.state.oh.us/ocapp/stewardship.html.

Ben Venue Laboratories, Inc. Cares

Caring for the environment is one of the many ways Ben Venue works to make a difference.  Each day, employees work to fulfill the company mission to provide their customers with pharmaceutical products that improve people’s health and quality of life.  This commitment to others also stems deeply into how the organization gives back to the community through many avenues including responsible environmental stewardship.  With support from all levels of the organization, the environmental health and safety management system continues to take on new life with each passing year.  From activities including the careful consideration for environmentally-friendly construction design to numerous grass-roots employee efforts, Ben Venue cares about the footprint it maintains and the impact on the environment.  Employees started a Waste Minimization and Recycling Team in 2005 to identify routes to recycle waste streams.  Successes include saving valuable landfill space and significantly reducing waste disposal costs. The company recycled and reused 35 tons of material in 2005, 360 tons in 2006 and over 730 tons in 2007. A precious-metal recycling program that began in 2007 recovered over 170 troy ounces of platinum for a return of more than $265,000. A water reclamation system installed in 2006 saved more than 7 million gallons of water in 2006 with a cost savings of $57,000.  The most recent accomplishment was the completion of the LEED Silver Certification application for its newest facility, a 90,000 square foot Lab and Office building.  President and COO, Thomas Murphy stated, “This commitment is at the heart of how we conduct business today and is sure to bring about even greater results for the future.”

Pictured Above:

Top Picture:  EPA Director Chris Korleski, Cheryl May - Manager of EHS, and Governor Ted Strickland

Bottom Picture:  Kevin Wemett - Government Affairs, Rob Fromuth - Sr VP Operations, Valerie Baker - Associate Director EHS, Chris Korleski - EPA Director, Cheryl May - Manager of EHS and Jason Kurtz - Manager of Communications and PR

 

Ben Venue Laboratories, Inc. Dedicates New 162,000 Square-Foot Expansion; 300 New Jobs to Bedford, Ohio

BEDFORD, OH—July 8, 2003—Ben Venue Laboratories, Inc. today celebrated the dedication of the latest expansion of its Bedford, Ohio pharmaceutical manufacturing facility. The new facility represents an addition of 162,000 square feet, and a capital investment of $82 million. The company has spent over $150 million in the last three years at its Bedford facility on further expansion and improvements.

“Ben Venue continues to grow to position itself to supply the expanding market for injectable pharmaceuticals,” said Thomas Russillo, President & COO. “We are proud to be the largest biotech employer in Northern Ohio and are creating about 300 new jobs with this expansion. We expect to continue growing even further.”

“Expansion of the Ben Venue facility underlines our strategic focus on the US market as an essential driver for continuous growth of the company,” stated Dr. Hans-Juergen Leuchs, Head of Corporate Board Division Operations and Member of the Board of Managing Directors at Boehringer Ingelheim.

With the new facility, Ben Venue now comprises 500,000 square feet at its Bedford location. The company is the world’s largest and most experienced contract developer and manufacturer of sterile pharmaceuticals. Its operations also include the Bedford Laboratories division, the third largest supplier of generic injectable products to theUS hospital market.

The new facility includes two new continuous filling lines with robotic traying that can accommodate either lyophilized (freeze-dried) or liquid products. It also includes six new 400 square foot lyophilizers with clean-in-place/steam-in-place capability, new sterilization equipment and a 10,000 unit per hour packaging line. Ben Venue Laboratories, Inc. is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies, headquartered in Ingelheim, Germany.

The Boehringer Ingelheim group of companies ranks among the 20 leading pharmaceutical corporations in the world and has 156 affiliated companies in 44 countries worldwide. Focusing on human pharmaceuticals and animal health, it posted revenues of $7.2 billion in 2002.

Since 1885, Boehringer Ingelheim has been a privately-held company with a long history of successfully marketed pharmaceutical innovations. Research and development, production and distribution facilities are located around the globe. In 2002, Boehringer Ingelheim’s R&D spending was more than $1.2 billion U.S. which is about a fifth of net sales in Prescription Medicines.

For more information on Boehringer Ingelheim, please see the international Internet website www.boehringer-ingelheim.com.

Ben Venue Laboratories, Inc. Awarded
National Cancer Institute Contract

BEDFORD, OH—March 3, 2003—Ben Venue Laboratories, Inc. has again been awarded a five year contract with the National Cancer Institute (NCI) to develop and manufacture investigational compounds that will be studied in a variety of tumor types. This award is one of an uninterrupted series of contracts that have been in place at Ben Venue since the late 1960’s, and is one of the longest running in NCI history. The amount of the award is $8 million and the term of the contract is from March 3, 2003 through February 29, 2008.

Ben Venue's NCI contract supports process development/scale-up, specialized process and analytical method development/validation as well as manufacturing of investigational anti-tumor agents. The NCI issued requests for proposals at two levels of effort, and it was expected that contracts would be awarded to two different manufacturers. Ben Venue bid on and was awarded both levels.

"Ben Venue is very proud to have been awarded this contract," said Thomas Russillo, President and COO. "It gives us the opportunity to assist in making promising new research therapies available for cancer patients. Through our contracts in the past, we have participated in the development of many of the leading oncologic agents used today, including methotrexate, daunorubicin, paclitaxel, cisplatin, BiCNU, dacarbazine (DTIC), Fludara and calcium leucovorin."

 
 
    © 2005 Ben Venue Laboratories. All rights reserved. The use of and access to the information on this site is subject to the terms and conditions set out in the Agreement to use the Ben Venue Laboratories web site.